AVCRF vs XTXXF
Avricore Health Inc. and Adastra Holdings Ltd., side by side — 3 fiscal years reported in CAD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | AVCRF | XTXXF |
|---|---|---|
| Revenue | CAD 4.7M | CAD 13.3M |
| Net income | CAD -668,977 | CAD -4.3M |
| Gross margin | 40.4% | 46.0% |
| Net margin | −14.4% | −32.2% |
| Return on equity | −33.6% | −21.1% |
| Diluted EPS | −CAD 0.01 | −CAD 0.07 |
| Dividend / share | · | · |
| Payout ratio | · | · |
| Free cash flow | CAD 823,521 | CAD 694,074 |
| Equity | · | · |
| Net debt / equity | · | · |
| Current ratio | · | 0.71× |
| Revenue CAGR 5y | · | · |
| Profit CAGR 5y | · | · |
XTXXF bills 2.9× the revenue of AVCRF, and both closed the last reported year at a loss.
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
Revenue by year
3 years side by side
| Fiscal year | AVCRF | XTXXF |
|---|---|---|
| FY2022 | CAD 1.8M | CAD 13.3M |
| FY2021 | CAD 122,808 | CAD 5.6M |
| FY2020 | CAD 33,030 | CAD 2.5M |
Net income by year
Bottom line
| Fiscal year | AVCRF | XTXXF |
|---|---|---|
| FY2022 | CAD -818,228 | CAD -4.3M |
| FY2021 | CAD -1.7M | CAD -2.7M |
| FY2020 | CAD -1.2M | CAD -7.6M |